Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 7/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10133959 | 0.89 | MET (0.54) | METKDRAXLAURKBATM | |
| SCHEMBL18040358 | 0.88 | MET (0.48) | METKDRAXLBRAFEGFR | |
| SCHEMBL371039 | 0.85 | MET (0.51) | METKDRAXLEGFR | |
| SCHEMBL368546 | 0.84 | MET (0.65) | METKDRAXLKIT | |
| SCHEMBL10133775 | 0.81 | MET (0.50) | METKDRAXLAURKB | |
| SCHEMBL10134550 | 0.80 | MET (0.67) | METKDRAXL | |
| SCHEMBL18040371 | 0.77 | MET (0.47) | METKDRAXL | |
| SCHEMBL363562 | 0.77 | MET (0.58) | METKDRAXLKIT | |
| SCHEMBL14949029 | 0.77 | MET (0.43) | METKDRAXLAURKB | |
| SCHEMBL18040366 | 0.73 | MET (0.52) | METKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | MET, RET, ABL1 | MET 1/4885KDR 48/4885AXL 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.